Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular carcinoma in mice using in vivo electrosonoporation

Yo Ichi Yamashita, Mitsuo Shimada, Ryosuke Minagawa, Eiji Tsujita, Norifumi Harimoto, Shinji Tanaka, Ken Shirabe, Jun Ichi Miyazaki, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

13 引用 (Scopus)

抜粋

We developed a new potent nonviral gene transfer method into mouse muscles in vivo named "electrosonoporation." We tried in this report to treat murine orthotopic hepatocellular carcinoma (HCC) by muscle-targeted mouse interleukin-12 (mIL-12) gene transfer using in vivo electrosonoporation. I.m. administration of the mIL-12 gene with electrosonoporation elevated serum IL-12 and IFN-γ and significantly prolonged the survival periods with both growth inhibition of orthotopic HCC and inhibition of spontaneous lung metastasis. The IL-12 gene therapy reduced the number of microvessels and induced more Mac-1-positive cells into HCC. These results show that muscle-targeted mIL-12 gene therapy for orthotopic HCC using in vivo electrosonoporation is very efficient and is thus promising for further clinical trial.

元の言語英語
ページ(範囲)1177-1182
ページ数6
ジャーナルMolecular Cancer Therapeutics
3
発行部数9
出版物ステータス出版済み - 9 1 2004

    フィンガープリント

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Yamashita, Y. I., Shimada, M., Minagawa, R., Tsujita, E., Harimoto, N., Tanaka, S., ... Maehara, Y. (2004). Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular carcinoma in mice using in vivo electrosonoporation. Molecular Cancer Therapeutics, 3(9), 1177-1182.